Weekly Digest – February 2025 Weekly Digest – February 2025 04 Feb 2025: Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates Pfizer has discontinued the development of its B7-H4-directed ADC, B7H4V, resulting in a $1 billion […]
Weekly Digest – February 2025 Weekly Digest – February 2025 06 Feb 2025: Merck announces phase 3 waveLINE-010 trial initiation evaluating Zilovertamab Vedotin, an investigational antibody-drug conjugate, for the treatment of patients with previously untreated diffuse large B-cell lymphoma Merck […]
Weekly Digest – February 2025 Weekly Digest – February 2025 06 Feb 2025: Anti-HER2 bispecific ADC JSKN003 received approval to initiate a phase 3 clinical study for the treatment of HER2-positive breast cancer Alphamab oncology and CSPC pharmaceutical received NMPA […]
Weekly Digest – January 2025 Weekly Digest – January 2025 27 Jan 2025: Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic Breast Cancer following disease progression after one or more endocrine therapies […]
Weekly Digest – January 2025 Weekly Digest – January 2025 30 Jan 2025: TROPION-Lung12 phase 3 trial initiated evaluating DATROWAY as part of adjuvant regimen for patients with early-stage Non-Small Cell Lung Cancer at high risk of relapse The TROPION-Lung12 […]
Weekly Digest – January 2025 Weekly Digest – January 2025 30 Jan 2025: Tubulis announces first patient dosed in Phase 1/2a trial evaluating ADC TUB-030 in advanced solid tumors TUB-030 entered clinical evaluation with the first patient dosed in the […]
Weekly Digest – January 2025 Weekly Digest – January 2025 29 Jan 2025: Vincerx Pharma and Oqory highlight promising data for Oqory’s TROP2 ADC, OQY-3258 Vincerx Pharma and Oqory highlighted Phase 1a/1b data for OQY-3258 It proposed a merger to advance […]
Weekly Digest – January 2025 Weekly Digest – January 2025 27 Jan 2025: Innate Pharma announces first patient dosed in phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors Innate Pharma began a […]
Weekly Digest – January 2025 Weekly Digest – January 2025 27 Jan 2025: Lantern Pharma unveils innovative AI-Powered module to improve the precision, cost and timelines of Antibody-Drug Conjugate development for cancer Lantern Pharma is advancing ADC development using its […]
Weekly Digest – January 2025 Weekly Digest – January 2025 22 Jan 2025: Zai Lab receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the treatment of Small Cell Lung Cancer (SCLC) Zai Lab’s First-in-class DLL3-targeting […]
